This new round of strategic investment will be mainly used for the development of products closer to customers.
TSimaging, an innovative medical imaging solution provider, recently signed a strategic investment agreement with Rimag. The proceeds will be used to create a product model and form closer to customers and explore the implementation of advanced medical imaging solutions to customers. Previously, it has raised CNY ten million from the Series A financing round.
Founded in 2016 by Tsinghua University and world-renowned scientists and experts in the industry, TSimaging specializes in the R&D of innovative medical imaging solutions. It aims to transform the scientific research results of the Tsinghua University Biomedical Imaging Research Center, adhering to the advanced medical solutions to serve doctors and aid patients with precise imaging based on the concept of diagnostic methods, a series of advanced imaging solutions.
TSimaging integrates professional imaging sequence, high signal-to-noise ratio imaging coil, artificial intelligence interpretation algorithm and image workstation together, forming a one-stop solution from imaging to reporting, which makes its clinical application more standardized and faster. In terms of market sales, the company has formed a product + service sales model for clinicians and cerebrovascular disease patients, with an annual market size of CNY 640 million and a service market capacity of CNY 58 billion. At present, the company has obtained two medical device registration certificates, formed more than 100 hospitals sales, product research and development, marketing and sales team of more than 30 people.